How do ALK-inhibitors work in ALK-positive lung cancer?

ALK Positive's Research Priorities - April 21, 2024 ALKtALKПодробнее

Lung Cancer | Striving for Consensus on the Management of ALK-Positive Lung CancerПодробнее

Striving for Consensus on the Management of ALK-Positive Lung CancerПодробнее

Dr. Ben Solomon Joins ALKtALK 1/21/24Подробнее

Ask the Expert: Dr. Ross CamidgeПодробнее

Dr Anna Minchom “Clinical Trial – an update"Подробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

ALK Positive Lung Cancer in 2023 and Beyond: Thinking Outside the Box with Dr. Alice ShawПодробнее

University of Michigan Initiative with Dr. Angel Qin moderated by ALK Patient, Jeff SturmПодробнее

Alecensa: Targeted Therapy for ALK-Positive Lung CancerПодробнее

ALK Inhibitors simplifiedПодробнее

Lung Cancer New Treatment 2023Подробнее

ALK 101 Part 5: Life After LorlatinibПодробнее

Updates and unmet needs in ALK-mutated lung cancerПодробнее

Judith Tam ALK Positive Non-Small Cell Lung Cancer Research Initiative Team Joins ALKtALK(3/26/23)Подробнее

Dr. Jamie Schneider, M.D. Ph.D. Joins ALKtALK (3/5/23)Подробнее

ALK 101 Part 1: I've Just Been Diagnosed With ALK Positive Lung CancerПодробнее

Dr Vamshi Krishna | CERTINIB - A Frontier in the 1st Line treatment of ALK+ve NSCLCПодробнее

Dr Shohbit Baijal “Alectinib or Brigatinib – that is the question”Подробнее

Dr Alastair Greystoke debates with Dr Tom Newsom-Davis “Lorlatinib – first or last?”Подробнее